Organization · Venture Capital
Vensana Capital
Vensana Capital is a venture capital and growth equity firm based in Minneapolis, focusing on innovations in medical technology to transform healthcare. The firm invests in development and commercial-stage companies within the medtech sector.
Overview
What Vensana Capital does
What Vensana Capital is
Vensana Capital is a venture capital and growth equity firm based in Minneapolis, focusing on innovations in medical technology to transform healthcare. The firm invests in development and commercial-stage companies within the medtech sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find Vensana Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Vensana Capital as a funder
Investment thesis
Vensana Capital believes that medtech innovation can improve healthcare outcomes while reducing costs. They target companies that can establish new clinical standards of care and enhance healthcare efficiency, accessibility, and cost-effectiveness.
Focus narrative
Vensana Capital invests in development and commercial stage companies within the medtech sector. Their primary focus areas include medical devices, diagnostics, data science, drug delivery, digital health, life science tools, and tech-enabled services. The firm typically makes investments ranging from $15 million to $50 million per company.
Value beyond capital
Vensana Capital adds value to its portfolio companies by providing not only capital but also operational, clinical, commercial, and business development expertise. Their dedicated team supports entrepreneurs in building successful medtech companies through the Vensana Innovation program.
Terms and economics
- Typical check
- $15,000,000–$50,000,000
Focus and fit
- Stages
- Growth Equity
- Sectors
- Medical Devices · Diagnostics · Digital Health
- Regions
- North America · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- CVRx
Portfolio context
Notable portfolio companies include: Abrus Bio: Focuses on innovative treatments. Alleviant Medical: Specializes in interventional heart failure technologies. Apella: Works on digitizing operating rooms. CVRx: Publicly traded company focused on heart disease solutions. Luna Diabetes: Develops automated insulin delivery solutions. SpyGlass Pharma: Engages in long-term drug delivery platforms for glaucoma patients. Vesper Medical: Acquired by Philips, focuses on image-guided therapy devices.
Common questions
What to know about Vensana Capital
Upseed classifies Vensana Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.